The advances in MNP-based ECBs for the detection of some of the most prominent cancer biomarkers (carcinoembryonic antigen (CEA), cancer antigen 125 (CA125), Herceptin-2 (HER2), etc.)and small biomolecules (glucose, dopamine, hydrogen peroxide, etc.)have been discussed in detail. This evidence concerns the gene MUC16 and cancer.